Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 80.62% is 112% above its 5-year average of -647.83%, near the high end of its 5-year range (-4325.98%–100.00%).
243.57% above its 12-month average of -56.15%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
80.62%
GROSS MARGIN AVG TTM
-56.15%
GROSS MARGIN AVG 3Y
-344.04%
GROSS MARGIN AVG 5Y
-647.83%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+243.57%
CURRENT VS 3Y AVG
+123.43%
CURRENT VS 5Y AVG
+112.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
+93.06%
vs the sector median at left
Bolt Biotherapeutics, Inc.
Market Cap
$6.92M
Gross Margin
80.62%
TTM Avg
-56.15%
3Y Avg
-344.04%
5Y Avg
-647.83%
Market Cap
$7.13M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$6.70M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
Market Cap
$6.67M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.20M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$7.20M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
Market Cap
$7.25M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $6.92M | 80.62% | -56.15% | -344.04% | -647.83% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | 64.28% | 69.38% | 65.33% | 71.21% |
| Aclarion, Inc. (ACON)vs › | $6.70M | -291.27% | -237.54% | -120.88% | -89.07% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.20M | 0.00% | 0.00% | 4.26% | 4.26% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.20M | 54.43% | 58.30% | 57.46% | 45.97% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| KALA BIO, Inc. (KALA)vs › | $7.27M | 0.00% | 0.00% | 8.55% | 24.65% |
| Longeveron Inc. (LGVN)vs › | $7.32M | 69.76% | 72.87% | 54.39% | 49.20% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.33M | 14.92% | 28.44% | 28.69% | 27.44% |
Gross Margin
80.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -680.77% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | -1108.15% |
| 2024-06-30 | -1110.43% |
| 2024-03-31 | 91.32% |
| 2023-12-31 | -681.33% |
| 2023-09-30 | -491.42% |
| 2023-06-30 | -991.70% |
| 2023-03-31 | -700.93% |
| 2022-12-31 | -1093.83% |
| 2022-09-30 | -798.34% |
| 2022-06-30 | -1258.22% |
| 2022-03-31 | -2161.38% |
| 2021-12-31 | -4325.98% |
| 2021-09-30 | -2471.41% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | -13580.60% |
| 2020-03-31 | -4038.41% |
| 2019-12-31 | -11338.46% |
| 2019-09-30 | -5055.37% |
| 2019-06-30 | -42413.79% |
| 2019-03-31 | -42413.79% |
